AVRA Medical Robotics, Inc. (OTC: AVMR) Files More Patents
AVRA Medical Robotics, Inc. (OTC: AVMR) provided an update on November 3, 2022, announcing the filing of an additional patent application for its semi-automated robotic system by patent counsel Locke Lord LLP. This follows their prior response to the US Patent Office regarding an earlier patent application. AVRA focuses on developing a fully autonomous medical robotic system utilizing AI and software, with current efforts aimed at creating a precision guidance system for minimally invasive procedures, specifically in aesthetic skin resurfacing.
- Filing an additional patent application strengthens AVRA's intellectual property portfolio.
- Focus on developing precision guidance systems meets growing market demand for medical robotics.
- None.
ORLANDO, FL, Nov. 03, 2022 (GLOBE NEWSWIRE) -- AVRA Medical Robotics, Inc. (“AVRA” or “the Company”) (OTC: AVMR) today issued the following update:
In October 2022, AVRA’s patent counsel, Locke Lord LLP, filed an additional patent application related to the Company’s semi-automated robotic system. Locke Lord LLP had previously responded to the US Patent Office on a prior patent application the Company had made that covered various apparatus and methods for its semi-automated robotic system.
About AVRA Medical Robotics
AVRA Medical Robotics, Inc., (OTC: AVMR) is a medical software and artificial intelligence company building a fully autonomous medical robotic system combining artificial intelligence, machine learning and proprietary software.
It is empowering doctors and the practice of surgery through the use of software and artificial intelligence.
AVRA is concentrating its research and development efforts to meet the rising expectations of patients and practitioners for the precision, efficiencies and safety offered by robotics, artificial intelligence and proprietary software when combined with proven medical devices and surgical instruments.
AVRA’s current focus is developing a treatment-independent precision guidance system, applicable to a variety of minimally and non-invasive procedures, to leverage the growing demand for practical medical robotic devices, with an initial focus on skin resurfacing aesthetic procedures.
For more information, visit the company’s website at www.avramedical.com.
Forward Looking Statements
This press release may contain statements that are not historical facts and are considered forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words “anticipate,” “assume,” “believe,” “estimate,” “expect,” “will,” “intend,” “may,” “plan,” “project,” “should,” “could,” “seek,” “designed,” “potential,” “forecast,” “target,” “objective,” “goal,” or the negatives of such terms or other similar expressions to identify such forward-looking statements. These statements relate to future events or AVRA’s future financial performance and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements.
Contact: aclug@avramedical.com
FAQ
What is the recent update from AVRA Medical Robotics regarding patents?
What is AVRA Medical Robotics focusing on in their development efforts?
What stock exchange is AVRA Medical Robotics listed on?
